{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '6. General good health and free of any disease or concomitant treatment that could interfere', 'with the interpretation of study results, as determined by the Investigator.', '7. Able to demonstrate the correct NS application technique (with the help of', 'parents/guardians/caregivers, if needed) at the Screening Visit (Visit 1).', '8. Willing and able to comply with all aspects of the protocol (with the help of', 'parents/guardians/caregivers, if needed).', '7.2.', 'Subject Exclusion Criteria', 'Subjects meeting any of the following criteria must not be enrolled in the study:', '1. Eligible females of childbearing potential who are known to be sexually active or', 'pregnant, will be excluded and referred for appropriate evaluation. If a girl has reached', 'puberty and achieved menarche (as determined by the Investigator),', 'parents/guardians/caregivers will be consulted to obtain consent for pregnancy testing', 'and permission to counsel the subject followed by counselling the subject by the', 'Investigator regarding the possible unknown risks associated with study medication', 'during pregnancy. Urine pregnancy test must be negative at the Screening Visit (Visit 1).', 'Male subjects who are known to be sexually active will also be excluded and referred', 'appropriately.', '2. Plans to travel outside the known pollen area for the investigational site for 24 hours or', 'longer during the last 7 days of the screening/run-in period.', '3. Plans to travel outside the known pollen area for the investigational site for 2 or more', 'consecutive days OR 3 or more days in total between the Randomization Visit (Visit 2)', 'and the Final Treatment Visit (Visit 4).', '4.', \"History of significant (based on Investigator's judgement) atopic dermatitis or rhinitis\", 'medicamentosa (within 60 days prior to the Screening Visit [Visit 1]).', '5. Treatment with any known strong cytochrome P450 (CYP)3A4 inducers (eg,', 'carbamazepine, phenytoin, rifabutin, rifampin, pioglitazone etc.) or strong inhibitors (eg,', 'azole antifungals, macrolide antibiotics) within 30 days prior to the Screening Visit (Visit', '1), or during the study.', '6. Non-vaccinated exposure to or active infection with chickenpox or measles within the', '21 days preceding Screening Visit (Visit 1).', '7. A known hypersensitivity to any corticosteroids or antihistamines or to either of the drug', 'components of the Investigational Product or its excipients.', '8. History of anaphylaxis and/or other severe local reaction(s) to skin testing.', '9. Any history or current use of alcohol or drug dependence at the Screening Visit (Visit 1),', 'as determined by the Investigator.', '10. History of positive test for human immunodeficiency virus, Hepatitis B or Hepatitis C', 'infection (parents/guardians/caregivers will be consulted to obtain consent).', '11. History and evidence of acute or significant chronic sinusitis or chronic purulent post', 'nasal drip at the Screening Visit (Visit 1).', 'Glenmark', 'CONFIDENTIAL', 'Page 32 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '12. Any of the following conditions (including but not limited to the following) that are', \"judged by the Investigator to be clinically significant and/or to affect the subject's ability\", 'to participate in this study:', 'impaired hepatic function.', 'any systemic infection.', 'hematological, hepatic, renal, endocrine disorder (except for hypothyroidism).', 'gastrointestinal disease.', 'malignancy (excluding basal cell carcinoma).', 'current neuropsychological condition with or without drug therapy.', '-', 'Subjects with history or current diagnosis of active ADHD can be included in the', 'study if symptoms of ADHD are considered stable by treating the physician and', 'such history is documented by the Investigator.', '-', 'Subjects with history or current diagnosis of ADHD on medications are eligible', 'for inclusion if they are on stable active drug therapy and have stable symptoms', 'for at least 30 days before the screening visit as documented in the medical', 'history by the Investigator. Subjects may not be withdrawn from ADHD', 'treatment medications during screening and/or throughout the study. If ADHD', 'treatment medications are planned to be withdrawn or withdrawn by the treating', 'physician during the study, then the subject should be considered ineligible or', 'early terminated, respectively.', 'cardiovascular disease (eg, uncontrolled hypertension).', 'respiratory disease other than mild asthma.', '13. Any major surgery (as assessed by the Investigator) within 4 weeks before the Screening', 'Visit (Visit 1).', '14. A requirement for the chronic use of tricyclic anti-depressants.', '15. Dependence (in the opinion of the Investigator) on nasal, oral, or ocular decongestants,', 'nasal topical antihistamines, or nasal steroids.', '16. Active pulmonary disorder or infection (including but not limited to bronchitis,', 'pneumonia, or influenza), upper respiratory tract or sinus infection within the 14 days', 'prior to the Screening Visit (Visit 1) or the development of respiratory infections during', 'the placebo run-in period. Subjects with mild asthma (as judged by the Investigator) are', 'allowable on the condition that treatment is limited to inhaled short-acting beta agonists', 'only (up to 8 puffs per day).', '17. Use of antibiotic therapy for acute conditions within 14 days prior to Screening Visit', '(Visit 1). Low doses of antibiotics taken for prophylaxis are allowed if the therapy was', 'started prior to the Screening Visit (Visit 1) and is expected to continue at the same stable', 'dose throughout the clinical study duration.', 'Glenmark', 'CONFIDENTIAL', 'Page 33 of 90']\n\n###\n\n", "completion": "END"}